{"created":"2023-07-27T06:29:20.203880+00:00","id":14105,"links":{},"metadata":{"_buckets":{"deposit":"873fd16f-32f8-4f3c-b1d8-275c4735b0b4"},"_deposit":{"created_by":3,"id":"14105","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"14105"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00014105","sets":["1132:1133:1134"]},"author_link":["20454"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-07-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"7","bibliographicPageEnd":"1527","bibliographicPageStart":"1525","bibliographicVolumeNumber":"25","bibliographic_titles":[{"bibliographic_title":"泌尿器外科 = Japanese journal of urological surgery"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"前立腺癌治療において, ホルモン療法はHugginsらの報告以来約70年経過した今も重要な位置を占めている. ただし, 当初の去勢術やエストロゲン剤による治療から, 最近ではLH-RHアゴニストとアンチアンドロゲン剤を併用するcombined androgen blockade(CAB)療法が用いられることが多い. しかし, 去勢単独治療と比較しての有用性については以前から論争があった. また最近, ホルモン療法に伴う有害事象が, ホルモン療法そのものに対する批判となっている. 以上の点につき, 私見を含め概説した. 「I CAB療法の作用機序」DHEAなどの副腎由来のアンドロゲンは本来アンドロゲン作用が弱いため, 前立腺癌治療において軽視されていたが, Labrieらは副腎性アンドロゲンが前立腺細胞内代謝(intracrine, 図1)により, テストステロンやDHTに変換されるため, 前立腺組織中のDHTの約40%が副腎由来であることを報告した.","subitem_description_type":"Abstract"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"医学図書出版"}]},"item_4_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.igakutosho.co.jp/","subitem_relation_type_select":"URI"}}]},"item_4_rights_23":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © 医学図書出版 | 許可を得て登録"}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN10064459","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0914-6180","subitem_source_identifier_type":"ISSN"}]},"item_4_text_2":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_text_value":"Present Status of ADT: 2. CAB and ADEs"},{"subitem_text_value":"[前立腺癌薬物療法研究会 発足記念シンポジウム記録]新展開を迎えた前立腺癌治療薬の位置づけPresent Status of ADT"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"並木, 幹夫"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-03"}],"displaytype":"detail","filename":"ME-PR-NAMIKI-M-1525.pdf","filesize":[{"value":"3.2 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ME-PR-NAMIKI-M-1525.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/14105/files/ME-PR-NAMIKI-M-1525.pdf"},"version_id":"a42118ec-d7e4-46c9-a0d3-0468ad0d2368"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"CAB and ADEs","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"CAB and ADEs"}]},"item_type_id":"4","owner":"3","path":["1134"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-03"},"publish_date":"2017-10-03","publish_status":"0","recid":"14105","relation_version_is_last":true,"title":["CAB and ADEs"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2024-05-20T07:32:35.666448+00:00"}